ISIN:SE0012558617

Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis

STOCKHOLM, July 8, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to c...

2020-07-08 14:57 998

Lipidor AB (publ) Formalizes Relationship With Subsidiary Emollivet AB Through License Agreement and Proposes Financing of Subsidiary

STOCKHOLM, Sweden, July 1, 2020 /PRNewswire/ -- Lipidor AB ("Lipidor" or the " Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. OnJune 30, Emollivet's Ext...

2020-07-01 08:06 897

New Disinfection Spray From Lipidor and Aurena Laboratories

STOCKHOLM, March 4, 2020 /PRNewswire/ -- In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply shortages. Lipidor (Nasdaq First North: LIPI) has previously developed a spray for hand ...

2020-03-04 15:20 790

Lipidor Announces Positive Topline Results of AKP01 Phase III Clinical Study Using Calcipotriol Spray Against Psoriasis

STOCKHOLM, Jan. 24, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI)  today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against mild to moderate plaque psoriasis. The randomised 277-patient study achieved its primary endpoint demonstra...

2020-01-24 23:21 821

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO Spray (AKP01) Phase III Study Targeting Psoriasis

STOCKHOLM, Sept. 9, 2019 /PRNewswire/ -- Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019.  Lipidor has develope...

2019-09-09 20:37 1650